

# CHEMO PHARMA LABORATORIES LIMITED

Registered Office: 5-Kumud Apartment Co. Op. HSG. SOC. Ltd., Karnik Road, Chikan Ghar, Kalyan, Dist. Thane - 421301

• Corporate Office : - Empire House, 3<sup>rd</sup> Floor, 214, Dr. D. N. Road, Fort, Mumbai - 400 001

• Tel.No. (022) 22078381, 22078382 • Fax No.: (022) 22074294 • CIN No.: L99999MH1942PLC003556 • PAN No.: AAACC2056K  
Website: www.thechemopharmalaboratoriesltd.com • Email ID: chemopharmalab@gmail.com

Date: 22<sup>nd</sup> May, 2017

To,  
Bombay Stock Exchange Ltd.  
Department of Corporate Services  
25<sup>th</sup> Floor, P. J. Towers, Dalal Street,  
Mumbai-400 001

Script ID: 506365

**SUBJECT: SUBMISSION OF FINANCIAL RESULTS, FORM A AND AUDITORS REPORT IN BOARD MEETING HELD ON 22<sup>ND</sup> MAY, 2017**

Dear Sirs,

Pursuant to Regulation 33 of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company in its meeting held on Monday, 22<sup>nd</sup> May, 2017 at 04:00 P.M. at Empire House, 3<sup>rd</sup> Floor, 214, Dr. D. N. Road, Fort, Mumbai - 400 001 approved the following:

1. Standalone Financial Results for the quarter and year ended 31<sup>st</sup> March, 2017
2. Form A for the year ended 31<sup>st</sup> March, 2017
3. Auditors Report on Standalone Financial Results for the year ended 31<sup>st</sup> March, 2017
4. Declaration regarding Audit Report with unmodified opinion

Thanking You.

Yours Faithfully,

**FOR CHEMO PHARMA LABORATORIES LIMITED**



**ASHOK SOMANI**  
**DIRECTOR**  
**(DIN No. - 03063364)**



# CHEMO PHARMA LABORATORIES LIMITED

REGISTERED OFFICE: 5-KUMUD APARTMENT CO. OP. HSG. SOC. LTD., KARNIK ROAD, CHIKAN GHAR, KALYAN, DIST. THANE- 421301

• CORPORATE OFFICE- EMPIRE HOUSE, 3<sup>RD</sup> FLOOR, 214, DR. D. N. ROAD, FORT, MUMBAI - 400 001

• TEL NO.: (022) 22078381, 22078382 • FAX NO.: (022)22074294

• CIN NO.: L99999MH1942PLC003556 • PAN NO.: AAACC2056K

WEBSITE: www.thechemopharmalaboratoriesltd.com

EMAIL ID: chemopharmalab@gmail.com

## ANNEXURE - I

Standalone Audited Financial Results for the Quarter and Year Ended 31st March, 2017

Part I

(Rs. in Thousand)

Sr. No.	Particulars	STANDLONE			
		Quarter Ended		Year Ended	
		31st March, 2017	31st March, 2016	31st March 2017	31st March 2016
		Audited	Audited	Audited	Audited
1	<b>Income from Operations</b>				
	a. Net Sales/ Income from Operation (Net of Excise Duty)	-	-	-	-
	b. Other Operating Income	53,114	2,544	56,080	4,919
	<b>Total Income from Operations (Net)</b>	<b>53,114</b>	<b>2,544</b>	<b>56,080</b>	<b>4,919</b>
2	<b>Expenses</b>				
	a. Cost Materials consumed	-	-	-	-
	b. Purchase of Stock-in-Trade	-	-	-	-
	c. Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	-	-	-	-
	d. Employee Benefits Expenses	234	150	805	542
	e. Depreciation and Amortisation Expenses	-	-	-	-
	f. Other Expenses (Any Item exceeding 10% of the Total Expenses relating to continuing Operations to be shown separately)	471	176	872	354
	i) Professional Charges	409	341	699	476
	ii) Share Registry Expenses	26	44	92	116
	iii) Annual Listing Fees	-	10	256	245
	<b>Total Expenses</b>	<b>1,140</b>	<b>721</b>	<b>2,724</b>	<b>1,733</b>
3	<b>Profit/(Loss) from Operation before Other Income, Finance Costs and Exceptional Items (1-2)</b>	<b>51,975</b>	<b>1,823</b>	<b>53,356</b>	<b>3,186</b>
4	Other Income	-	-	-	-
5	<b>Profit/(Loss) from Ordinary Activities before Finance Costs and Exceptional Items (3+/-4)</b>	<b>51,975</b>	<b>1,823</b>	<b>53,356</b>	<b>3,186</b>
6	Finance Costs	-	-	-	-
7	<b>Profit/(Loss) from Ordinary Activities after Finance Costs but before Exceptional Items (5+/-6)</b>	<b>51,975</b>	<b>1,823</b>	<b>53,356</b>	<b>3,186</b>
8	Exceptional Items	-	-	-	-
9	<b>Profit/(Loss) from Ordinary Activities before Tax (7+/-8)</b>	<b>51,975</b>	<b>1,823</b>	<b>53,356</b>	<b>3,186</b>
10	Tax Expenses	6,515	1,018	6,515	1,018
11	<b>Net Profit/(Loss) from ordinary Activities after Tax (9+/-10)</b>	<b>45,460</b>	<b>805</b>	<b>46,841</b>	<b>2,168</b>
12	Extra Ordinary Items (Net of Tax Expenses Rs. _____ Lacs)	-	-	-	-
13	<b>Net Profit/(Loss) for the Period (11+/-12)</b>	<b>45,460</b>	<b>805</b>	<b>46,841</b>	<b>2,168</b>
14	Share of Profit/(Loss) of Associates*	-	-	-	-
15	Minority Interest	-	-	-	-
16	<b>Net Profit/(Loss) after Taxes, Minority Interest and Share of Profit / (Loss) of Associates (13+/-14+/-15)*</b>	<b>45,460</b>	<b>805</b>	<b>46,841</b>	<b>2,168</b>



# CHEMO PHARMA LABORATORIES LIMITED

REGISTERED OFFICE: 5-KUMUD APARTMENT CO. OP. HSG. SOC. LTD., KARNIK ROAD, CHIKAN GHAR, KALYAN, DIST. THANE- 421301

• CORPORATE OFFICE- EMPIRE HOUSE, 3<sup>RD</sup> FLOOR, 214, DR. D. N. ROAD, FORT, MUMBAI - 400 001

• TEL NO.: (022) 22078381, 22078382 • FAX NO.: (022)22074294

• CIN NO.: L99999MH1942PLC003556 • PAN NO.: AAACC2056K

WEBSITE: [www.thechemopharmalaboratoriesltd.com](http://www.thechemopharmalaboratoriesltd.com)

EMAIL ID: [chemopharmalab@gmail.com](mailto:chemopharmalab@gmail.com)


17	Paid-up Capital Equity Share (Face Value of Rs.10/- each)	15,000	15,000	15,000	15,000
18	Reserves excluding Revaluation Reserve as per Balance Sheet of Previous Accounting Year	85,226	38,385	85,226	38,385
19i	<b>Earnings per Share (before Extra Ordinary Items) (of Rs.____/- each) (not Annualised):</b>				
	a. Basic	30.31	0.54	31.23	1.45
	b. Diluted				
19ii	<b>Earnings per Share (after Extra Ordinary Items) (of Rs.____/- each) (not Annualised):</b>				
	a. Basic	30.31	0.54	31.23	1.45
	b. Diluted				

A PARTICULARS OF SHAREHOLDING					
1	Public Shareholding				
	- Number of shares	10,81,719	10,81,719	10,81,719	10,81,719
	- Percentage of shareholding	72.12	72.12	72.12	72.12
19	Promoters and Promoter Group shareholding**				
	a) Pledged/Encumbered				
	- Number of shares	NIL	NIL	NIL	NIL
	- Percentage of shares (as a % of the total)	NIL	NIL	NIL	NIL
	- Percentage of shares (as a % of the total share capital)	NIL	NIL	NIL	NIL
	b) Non-Encumbered				
	- Number of shares	4,18,281	4,18,281	4,18,281	4,18,281
	- Percentage of shares (as a % of the total)	100	100	100	100
	- Percentage of shares (as a % of the total share capital)	27.88	27.88	27.88	27.88

#### Notes :

- The above Audited Financial Results for the Quarter and Year Ended 31.03.2017 have been reviewed by the Audit Committee in their Meeting held on 22.05.2017 and approved by the Board of Directors of its Meeting held on 22.05.2017. The Limited Review Report of Auditors M/s VMD & Co. was also taken on record by the Board in its Meeting.
- The Company is not having any Subsidiary Company / Associate Company. These are Standalone Results as intimated to BSE.
- The Company is having one segment.

For Chemo - Pharma Laboratories Limited



Ashok Somani  
Director

Place : Mumbai  
Date : 22nd May, 2017



# CHEMO PHARMA LABORATORIES LIMITED

REGISTERED OFFICE: 5-KUMUD APARTMENT CO. OP. HSG. SOC. LTD., KARNIK ROAD, CHIKAN GHAR, KALYAN, DIST. THANE- 421301  
 • CORPORATE OFFICE- EMPIRE HOUSE, 3<sup>RD</sup> FLOOR, 214, DR. D. N. ROAD, FORT, MUMBAI - 400 001  
 • TEL NO.: (022) 22078381, 22078382 • FAX NO.: (022)22074294  
 • CIN NO.: L99999MH1942PLC003556 • PAN NO.: AAACC2056K  
 WEBSITE: www.thechemopharmalaboratoriesltd.com  
 EMAIL ID: chemopharmalab@gmail.com

## STANDALONE STATEMENT OF ASSETS & LIABILITIES AS ON 31ST MARCH, 2017 AS PER CLAUSE 41 OF THE LISTING AGREEMENT

(Rs. in Thousands)


SR. NO.	PARTICULARS	AS AT 31.03.2017 RUPEES	AS AT 31.03.2016 RUPEES
<b>A</b>	<b><u>EQUITY AND LIABILITIES</u></b>		
<b>1</b>	<b>SHAREHOLDERS' FUNDS</b>		
	(a) Share Capital	15,000	15,000
	(b) Reserves and Surplus	85,226	38,385
	<b>Sub Total - Shareholders' Funds</b>	<b>1,00,226</b>	<b>53,385</b>
<b>2</b>	<b>NON CURRENT LIABILITIES</b>		
	(a) Other Long Term Liabilities	1,197	1,197
	<b>Sub Total - Non- Current Liabilities</b>	<b>1,197</b>	<b>1,197</b>
<b>3</b>	<b>CURRENT LIABILITIES</b>		
	(a) Other Current Liabilities	276	535
	(b) Short Term Provisions	5,491	225
	<b>Sub Total - Current Liabilities</b>	<b>5,767</b>	<b>760</b>
	<b>TOTAL - EQUITY AND LIABILITIES</b>	<b>1,07,190</b>	<b>55,342</b>
<b>B</b>	<b><u>ASSETS</u></b>		
<b>1</b>	<b>NON CURRENT ASSETS</b>		
	(a) Fixed Assets	94	44
	(b) Non Current Investment	188	16,844
	(c) Non Term Loan & Advances	15,670	16,561
	<b>Sub Total - Non- Current Assets</b>	<b>15,952</b>	<b>33,449</b>
<b>2</b>	<b>CURRENT ASSETS</b>		
	(a) Cash & Cash Equivalents	68,733	4,388
	(b) Short Term Loans and Advances	22,505	17,505
	<b>Sub Total - Current Assets</b>	<b>91,238</b>	<b>21,893</b>
	<b>TOTAL - ASSETS</b>	<b>1,07,190</b>	<b>55,342</b>
		-	-

Consequent to the notification of Revised Schedule VI under the Companies Act, 1956, the Assets & Liabilities for the Statements year ended 31.03.2017 are prepared as per revised Schedule VI. Accordingly, the previous year figures have also been re-classified conform to this year's classification.



Place: Mumbai  
 Date : 22nd May, 2017

By order of Board  
 For Chemo Pharmal Laboratories Ltd.

  
 ASHOK SOMANI  
 DIRECTOR

# CHEMO PHARMA LABORATORIES LIMITED






Registered Office: 5-Kumud Apartment Co. Op. HSG. SOC. Ltd., Karnik Road, Chikan Ghar, Kalyan, Dist. Thane - 421301

• Corporate Office : - Empire House, 3<sup>rd</sup> Floor, 214, Dr. D. N. Road, Fort, Mumbai - 400 001

• Tel.No. (022) 22078381, 22078382 • Fax No.: (022) 22074294 • CIN No.: L99999MH1942PLC003556 • PAN No.: AAACC2056K

Website: www.thechemopharmalaboratoriesltd.com • Email ID: chemopharmalab@gmail.com

## FORM A as per Regulation 33 (3)(d) of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015

1. Name of the Company:	CHEMO PHARMA LABORATORIES LIMITED
2. Annual Financial Statements for the year ended	31 <sup>st</sup> March, 2017
3. Type of Audit observation	Un-Qualified
4. Frequency of observation	-
5. To be signed by-	
• CEO – SHANTA SOMANI	
• CFO – ASHOK SOMANI	
• Auditor of the Company – VMD & Co.	 For VMD & Co.  Partner CA Amit S. Ganpule Mem. No. 114222
• Audit Committee Chairman – G. K. JOSHI	



**INDEPENDENT AUDITOR'S REPORT**

To The Members of CHEMO PHARMA LABORATORIES LTD.

**Report on the Financial Statements**

We have audited the accompanying financial statements of **Chemo Pharma Laboratories Ltd.** ('the Company'), which comprise the Balance Sheet as at March 31, 2017, the Statement of Profit and Loss and the Cash Flow Statement for the year then ended and a summary of significant accounting policies and other explanatory information.

**Management's responsibility for the Financial Statements**

The Company's Board of Directors is responsible for the matters stated in section 134 (5) of the Companies Act, 2013 ( "the Act")with respect to the preparation of these financial statements that give a true and fair view of the financial position, financial performance and cash flows of the Company in accordance with the Accounting principles generally accepted in India, including the accounting standards specified under section 133 of the act, read with rule 7 of the companies (Accounts) Rules, 2014. This responsibility also includes the maintenance of adequate accounting records in accordance with the provisions of the act for safeguarding the assets of the company and for preventing and detecting the frauds and other irregularities; selection and application of appropriate accounting policies; making judgment and estimates that are reasonable and prudent; and design, implementation and maintenance of internal financial control, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

**Auditors Responsibility**

Our responsibility is to express an opinion on these financial statements based on our audit.

We have taken into account the provisions of the Act, the accounting and auditing standards and matters which are required to be included in the audit report under the provisions of the act and the rules made there under.

We conducted our audit in accordance with the Standards on Auditing specified under section 143(10) of the Act. Those Standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor



considers internal control relevant to the Company's preparation of the financial statements that give true and fair view in order to design audit procedures that are appropriate in the circumstances but not for the purpose of expressing an opinion on whether the has an adequate internal financial controls system over financial reporting in place and the operating effectiveness of such controls. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of the accounting estimates made by company's directors, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the financial statements.

### **Opinion**

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid financial statements, give the information required by the Act in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at March 31, 2017 and its profit and its cash flows for the year ended on that date.

### **Report on Other Legal and Regulatory Requirements**

1. As required by the Companies (Auditor's Report) Order 2016 ("the order") issued by the Central Government of India in terms of section 143 (11) of the Act, we give in the Annexure A, a statement on the matters specified in the paragraph 3 and 4 of the order.

2. As required by section 143(3) of the Act, we report that:

- a. we have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purpose of our audit;
- b. in our opinion proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books;
- c. the Balance Sheet, Statement of Profit and Loss and Cash Flow Statement dealt with by this report are in agreement with the books of account;
- d. in our opinion, the Balance Sheet, Statement of Profit and Loss and Cash Flow Statement comply with the Accounting Standards referred to in section 133 of the Companies Act, 2013, read with rule 7 of the Companies (Accounts) Rules, 2014.
- e. on the basis of written representations received from the directors as on March 31, 2017, and taken on record by the Board of Directors, none of the directors is disqualified as on March 31, 2017, from being appointed as a director in terms of sub section (2) of section 164 of the Companies Act, 2013.
- f. With respect to the adequacy of the internal financial controls over financial reporting of the company and the operating effectiveness of such controls, refer to our separate Report in 'Annexure B'.



g. With respect to the other matters included in the Independent Auditor's report, in our opinion and to the best of our information and according to the explanations given to us:

1) The company has disclosed the impact of pending litigation on its financial position in its financial statement.

2) The company has made provision, as required under the applicable law or Accounting Standards, for material foreseeable losses, if any, on long term contracts including derivative contracts.

3) There has been no delay in transferring amounts, required to be transferred, to the Investor Education and Protection Fund by Company.

4) The Company has provided requisite disclosures in its financial statements as to holdings as well as dealings in Specified Bank notes during the period from 8<sup>th</sup> November, 2016 to 30 December, 2016 and these are in accordance with the books of accounts maintained by the Company. Refer Note 20 to the financial statements.

For VMD & Co.  
Chartered Accountants  
FRN: 125002W

  
CA Amit Ganpule  
Partner

MIRN: 114222

Place : Mumbai

Date: 22<sup>nd</sup> May 2017

No. : A/02/0517





## ANNEXURE 'A' TO THE INDEPENDENT AUDITORS' REPORT

(Referred to in Paragraph 2 under 'Report on Other Legal and Regulatory Requirements' section of our report of even date)

Report on Companies (Auditor's Report) Order, 2016 ('the Order') issued by the Central Government in terms of section 143(11) of the Companies Act, 2013

- (i) (a) The Company is maintaining proper records showing full particulars, including quantitative details and situation of fixed assets.
- (b) Fixed Assets were physically verified by the Management during the current year. In our opinion, the frequency of verification is reasonable having regard to the size of the Company and the nature of its Fixed Assets.
- (c) The company does not have immovable property, Hence the paragraph 3(i)(c) of the order is not applicable.
- (ii) The company does not have any inventory accordingly, the paragraph 3(ii) of the order is not applicable.
- (iii) (a) The company has given loans to one party covered in the register maintained under section 189 of the Companies Act, 2013.
- (b) In the case of the loans granted to the company in the register maintained under section 189 of the Act, the borrowers have been regular in the payment of the interest as stipulated. The terms of arrangements do not stipulate any repayment schedule and are repayable on demand. Accordingly, paragraph 3(iii)(b) of the Order is not applicable to the Company in respect of repayment of the principal amount.
- (c) There are no overdue amounts in respect of the loans granted to the companies listed in the register maintained under section 189 of the Act.
- (iv) In our opinion and according to the information and explanations given to us, the Company has complied with the provisions of Sections 185 and 186 of the Act in respect to the loans and investments made.
- (v) In our opinion and according to the information and explanations given to us, no fixed deposits were accepted from the public.
- (vi) In our opinion, clause 3(vi) of the order for maintenance of the cost records under section 148(1) of the Companies Act 2013 is not applicable to the Company.
- (vii) (a) According to the information and explanations given to us and on the basis of our examination of the records of the Company, amount deducted/accrued in the books of account in respect of undisputed statutory dues including Provident Fund, Income Tax, Value added Tax, Service Tax, Cess and other material Statutory dues have been regularly deposited during the year by the Company with the appropriate authorities.
- According to the information and explanations given to us, no undisputed amounts payable in respect of Provident Fund, Income Tax, Value added Tax, Service Tax, Cess and other material Statutory dues were in arrears as at 31<sup>st</sup> March, 2017 for a period of more than six months from the date they become payable.



(b) According to the information and explanations given to us, the dues in respect of sales tax, income tax, custom duties, wealth tax, excise duty and cess that have been deposited with the appropriate authorities except in cases where there is a dispute. The details of dispute and the forum where such disputes are pending is given below:

Name of the Statute	Nature of the dues	Amount (Rs.)	Forum where dispute is pending
Central Sales Tax Maharashtra Sales Tax	Central sales tax & Maharashtra Sales Tax	18,05,093	Appeal before sales tax authority
Income Tax Act	Penalty Tax	60,47,659	Appeal before ITAT
Income Tax Act	Income Tax	31,77,291	Appeal before ITAT
Central Sales Tax Act	Central Sales Tax	1,67,560	Company has filed an appeal against order in High Court
Maharashtra Sales Tax Act	Sales Tax	9,50,255	Company has filed an appeal against order in High Court

- (viii) The company does not have any loans or borrowings from any Financial Institution, Banks, Government or Debenture Holders during the year. Accordingly, paragraph 3(vii) of the order is not applicable.
- (ix) The company has not raised moneys by way of initial public offer or further public offer (including debt instruments) or term loans and hence reporting under clause 3(ix) of the order is not applicable.
- (x) Based on the audit procedures performed and information and explanations given to us, we report that no fraud on or by the company has been noticed or reported during the course of our audit.
- (xi) The Company has not paid any managerial remuneration for the year hence clause 3(xi) of the order is not applicable.
- (xii) The Company is not a Nidhi Company and hence reporting under clause 3 (xii) of the order is not applicable.
- (xiii) In our opinion and according to the information and explanations given to us the Company is in compliance with section 177 and 188 of the act, where applicable, for all transactions with the related parties and the details of related party transactions have been disclosed in the financial statements as required by the applicable accounting standards.
- (xiv) During the year, the Company has not made any preferential allotment or private placement of shares or fully or partly convertible debentures and hence reporting under clause 3(xiv) is not applicable to the Company.



- (xv) In our opinion and according to the information and explanations given to us, during the year the Company has not entered into any non-cash transactions with its directors or persons connected to its Directors and hence provisions of Section 192 of the Act are not applicable.
- (xvi) The Company is not required to be registered under Section 45-I of the Reserve Bank of India Act, 1934.

For VMD & Co.  
Chartered Accountants  
FRN: 125002W

  
CA Amit Ganpule  
Partner

MRN: 114222

Place : Mumbai

Date: 22<sup>nd</sup> May 2017

No. : A/02/0517



**Annexure B To The Independent Auditor's Report of even date on the Financial Statements of Chemo Pharma Laboratories Ltd.**

**Report on the Internal Financial Controls under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 ("the Act")**

To the Members of Chemo Pharma Laboratories Ltd.

We have audited the internal financial controls over financial reporting of Chemo Pharma Laboratories Ltd. ("the Company") as of 31 March 2017 in conjunction with our audit of the financial statements of the Company for the year ended on that date.

**Management's Responsibility for Internal Financial Controls**

The Company's Management is responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India (the "Guidance Note"). These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to the Company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

**Auditor's Responsibility**

Our responsibility is to express an opinion on the Company's internal financial controls over financial reporting based on our audit. We conducted our audit in accordance with the Guidance Note and the Standards on Auditing as specified under section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls, both applicable to an audit of Internal Financial Controls and, both issued by the Institute of Chartered Accountants of India. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the internal financial controls system over financial reporting.



## Meaning of Internal Financial Controls Over Financial Reporting

A company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control over financial reporting includes those policies and procedures that

- (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company;
- (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorisations of management and directors of the company; and
- (3) provide reasonable assurance regarding prevention or timely detection of unauthorised acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.


## Inherent Limitations of Internal Financial Controls Over Financial Reporting

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

## Opinion

In our opinion, the Company has, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at 31 March 2017, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India.

For VMD & Co.  
Chartered Accountants  
FRN: 125002W

  
CA Amit Ganpule  
Partner

MRN: 114222  
Place : Mumbai  
Date: 22<sup>nd</sup> May 2017  
No. : A/02/0517



# CHEMO PHARMA LABORATORIES LIMITED

Registered Office: 5-Kumud Apartment Co. Op. HSG. SOC. Ltd., Karnik Road, Chikan Ghar, Kalyan, Dist. Thane - 421301

• Corporate Office : - Empire House, 3<sup>rd</sup> Floor, 214, Dr. D. N. Road, Fort, Mumbai - 400 001





• Tel.No. (022) 22078381, 22078382 • Fax No.: (022) 22074294 • CIN No.: L99999MH1942PLC003556 • PAN No.: AAACC2056K

Website: www.thechemopharmalaboratoriesltd.com • Email ID: chemopharmalab@gmail.com

## DECLARATION

Declaration regarding Un-Modified Audit Report in respect Standalone Financial Statements for the financial year 2016-2017 under SEBI (Listing Obligations and Disclosure Requirements)(Amendment) Regulations, 2016

We hereby declare that we have submitted the Audit Reports in respect of Standalone Financial Statements for the year 2016-2017, along with the financial results on 22<sup>nd</sup> May, 2017. We hereby confirm that auditors have expressed an unmodified opinion in their audit reports on standalone and consolidated financial statements

1. Name of the Company:	<b>CHEMO PHARMA LABORATORIES LIMITED</b>
2. Annual Financial Statements for the year ended	31 <sup>st</sup> March, 2017
3. Type of Audit observation	Un-Qualified
4. Frequency of observation	-
5. To be signed by-	
• CEO – SHANTA SOMANI	
• CFO – ASHOK SOMANI	
• Auditor of the Company – VMD & Co.	 For VMD & Co.  Partner CA/Amit S. Ganpule Mem. No. 114222
• Audit Committee Chairman –G. K. JOSHI	